Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 16NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Breast 4Genitourinary 2Gastrointestinal 1

Conditions

Colonic Neoplasms 226Colorectal Neoplasms 203Rectal Neoplasms 194Pancreatic Neoplasms 158Carcinoma, Hepatocellular 109Stomach Neoplasms 94Esophageal Neoplasms 81Liver Neoplasms 72Breast Neoplasms 68Lung Neoplasms 53Neoplasms 48Carcinoma, Non-Small-Cell Lung 47Neoplasm Metastasis 46Ovarian Neoplasms 44Sarcoma 43Bile Duct Neoplasms 38Gallbladder Neoplasms 37Melanoma 33Anus Neoplasms 31Prostatic Neoplasms 30Adenocarcinoma Of Esophagus 29Lymphoma, Non-Hodgkin 28Carcinoma, Renal Cell 28Uterine Cervical Neoplasms 27Osteosarcoma 27Gastrointestinal Stromal Tumors 27Gastrointestinal Neoplasms 27Neuroectodermal Tumors, Primitive, Peripheral 25Neuroblastoma 25Wilms Tumor 24

Interventions

veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hereditary Breast and Ovarian Cancer Syndrome × Gastrointestinal × Clear all
NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡